As Taiwan transitions into a super-aged demographic profile, the National Health Insurance (NHI) global budget has crossed the critical threshold of NT$1 trillion, demonstrating an annualized growth rate of 5.5% to reach an all-time financial peak. Concurrently, the newly allocated budget for New Medical Technologies has settled at NT$7.858 billion, a growth vector that clinical leaders and patient advocacy groups argue lags behind the rapid pace of biopharma innovation. Policy experts are urging the government to implement structured, rule-based budgetary escalations rather than relying on arbitrary ad-hoc negotiations, pointing to advanced global economic models to balance fiscal sustainability with rapid patient access to novel therapeutics.
Read more
